Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/06/2023 
Veterinary Medicinal Products - Other variation 
amended 
on 
SmPC, 
Labelling and 
PL 
R/0015 
Renewal of the marketing authorisation. 
15/09/2022 
07/11/2022 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka in the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
approved indication remains favourable and therefore 
recommended the renewal of the marketing authorisation 
with unlimited validity. 
IB/0014 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
20/05/2022 
07/11/2022 
SmPC and PL 
Section 4.5 of SmPC and Section 2 of PL were updated to 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
add new information regarding interaction between 
praziquantel and efavirenz in line with the wording 
recommended by CMDh following 
PSUSA/00002503/202104 procedure. 
IB/0013/G 
This was an application for a group of variations. 
20/01/2022 
n/a 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
B.I.c.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Deletion of a non-significant specification parameter 
(e.g. deletion of an obsolete parameter) 
B.I.c.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Tightening of specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
Page 2/7 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0012 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
19/01/2022 
07/11/2022 
SmPC and PL 
To update the self-life in Annex I section 6.3, from 2 years 
life of the finished product - As packaged for sale 
to 3 years, along with minor editorial changes in the 
(supported by real time data) 
package leaflet. 
IB/0011 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
25/03/2021 
03/02/2022 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0010/G 
This was an application for a group of variations. 
19/01/2021 
03/02/2022 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
the MAH 
N/0009 
Minor change in labelling or package leaflet not 
09/11/2020 
03/02/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0008/G 
This was an application for a group of variations. 
25/06/2020 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0007 
C.I.11.z - Introduction of, or change(s) to, the 
20/11/2019 
02/06/2020 
Annex II and 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Labelling 
IB/0006 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
06/06/2019 
02/06/2020 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0005/G 
This was an application for a group of variations. 
01/03/2019 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
IB/0004/G 
This was an application for a group of variations. 
15/02/2019 
11/03/2019 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/11/2018 
11/03/2019 
SmPC 
Veterinary Medicinal Products - Other variation 
IB/0001/G 
This was an application for a group of variations. 
16/08/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.b - Change in test procedure for AS or 
starting material/reagent/intermediate - Deletion of 
a test procedure for the AS or a starting 
material/reagent/intermediate, if an alternative test 
procedure is already authorised 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0002/G 
This was an application for a group of variations. 
18/07/2018 
31/08/2018 
SmPC, 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Labelling and 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.z - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Other variation 
Page 7/7 
 
 
 
 
 
 
 
